|
|
Epigenomics AG - Comparative Business Analysis Snapshot
Business Description
Epigenomics AG. The Group's principal activity is to conduct molecular diagnosis for the early detection and treatment of cancer and other complex diseases. The Group's products are based on DNA methylation, which are aimed at making early detection and treatment easier, more accurate and more convenient for the patient. The Group compares patient's cells against healthy and sick reference samples, which enables an exact diagnosis of disease at a very early stage and provides physicians with essential information to help guide the appropriate therapy. The group operates in Europe and North America.
Competitor Analysis
This analysis compares Epigenomics AG with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
